Ocular Therapeutix公司 OCUL 深 沪
已收盘 07-02 16:00:00 美东时间
9.64
+0.170
+1.80%
华盛通- 最 高9.74
- 今 开9.56
- 成交量 183.31万股
- 最 低 9.41
- 昨 收 9.47
- 总市值 21.11亿
- 52周最高 16.44
- 市盈率 静 --
- 换手率 0.84%
- 52周最低 6.2301
- 委 比 69.99%
- 总股本 2.19亿
- 历史最高 44.19
- 量 比 0.54
- 振 幅 3.48%
- 历史最低 1.995
- 每 手 1
- 风险率 1.73%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多OCUL’s OTX-TKI Extension Study: Long-Term Safety Data Could Shape Wet AMD Market
Ocular Therapeutix Inc ($OCUL) announced an update on their ongoing clinical st...
07-02 00:31
美股大行评级 | 潜在涨幅135.66%！Ocular Therapeutix获Chardan Capital升目标价至23美元，维持"买入"评级
今日重点评级关注：Chardan Capital：维持Ocular Therapeutix"买入"评级，目标价从21美元升至23美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从30美元升至40美元
06-26 17:42
Chardan Capital Maintains Buy on Ocular Therapeutix, Raises Price Target to $23
Chardan Capital analyst Andreas Argyrides maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and raises the price target from $21 to $23.
06-25 21:34
Ocular Therapeutix Plans Q4 2026 NDA Submission For AXPAXLI In Wet AMD Based On SOL-1 Data, Removes SOL-R Efficacy From Filing And Extends Trial Timeline To 2028
Per May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safety plus interim SOL-R safety data Ocular to conduct interim SOL-R safety analysis in 4Q 2026 to reach >300 patients of safety data across SOL-1 and SOL-R, in alignment with FDA requirements Complete AX...
06-17 20:46
Ocular Therapeutix says FDA aligns on AXPAXLI wet AMD NDA plan for Q4 2026 submission
Ocular Therapeutix says FDA aligns on AXPAXLI wet AMD NDA plan for Q4 2026 submission Ocular Therapeutix reached FDA alignment to file a 505(b)(2) NDA for AXPAXLI in wet AMD in 4Q 2026. Submission to rely on SOL-1 Week 52 efficacy and safety data, supported by an interim SOL-R safety readout to exce
06-17 20:46
Ocular Therapeutix grants inducement awards of options for 51,775 shares, RSUs for 16,950 shares to new hires
Ocular Therapeutix grants inducement awards of options for 51,775 shares, RSUs for 16,950 shares to new hires Ocular Therapeutix granted inducement equity awards to seven newly hired non-executive employees, effective June 1, 2026. Awards include stock options for 51,775 shares, exercise price $8.93
06-05 19:00
美股大行评级 | 潜在涨幅20%！15家机构集体上调AMD目标价；Lumentum、神经分泌生物科学、伊顿公司、美国电力等获多家大行上调目标价
今日重点评级关注：Citizens：维持Avalo Therapeutics"跑赢大市"评级，目标价从52美元升至62美元；BTIG：维持Avalo Therapeutics"买入"评级，目标价从40美元升至58美元
05-07 12:37
RBC Capital Reiterates Outperform on Ocular Therapeutix, Maintains $30 Price Target
RBC Capital analyst Lisa Walter reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Outperform and maintains $30 price target.
05-06 23:49
Ocular Therapeutix shares are trading lower after the company reported worse-than-expected Q1 financial results.
Ocular Therapeutix shares are trading lower after the company reported worse-th...
05-06 02:13
财报速睇 | Ocular Therapeutix公司 2026财年Q1营收0.11亿美元，同比增长0.8%；归母净利润亏损0.89亿美元，同比亏损扩大38.3%
华盛资讯5月5日讯，Ocular Therapeutix公司公布2026财年Q1业绩，公司Q1营收0.11亿美元，同比增长0.8%，归母净利润亏损0.89亿美元，同比亏损扩大38.3%。
05-05 19:46
